MSD V-PLEX · 7-Plex

Active or Total GLP-1 Options

MSD Metabolic 7-Plex Panel — Enteroinsular Axis Profiling

Q: What is the difference between Panel 1 and Panel 2 beyond GLP-1?

The six non-GLP-1 analytes are identical between Panel 1 and Panel 2: C-Peptide, GIP (total), Glucagon, Insulin, Leptin, and PYY (total). The only difference is the GLP-1 assay — total GLP-1 in Panel 1, active GLP-1 in Panel 2. This means your choice between panels depends entirely on whether your research question requires total L-cell secretion (Panel 1) or receptor-activatable incretin (Panel 2). If your study needs both active and total GLP-1 — for example, to calculate the active/total ratio as a measure of DPP-IV activity — the 22-Plex includes active, inactive, and total GLP-1 in a single panel.

Q: Are these assays validated for clinical diagnostic use?

No. The Metabolic 7-Plex is manufacturer-validated for research use only (RUO). It is suitable for preclinical studies, cohort research, biomarker discovery, and therapeutic development. It is not validated for clinical diagnostic procedures or patient management decisions. All data is reported with the explicit disclaimer that it should not be used as the sole basis for clinical decision-making.

The most widely used metabolic hormone multiplex panel on the MSD platform: C-Peptide, GIP, GLP-1, Glucagon, Insulin, Leptin, and PYY — seven hormones spanning the gut-pancreas-adipose axis from a single 25 µL sample of protease inhibitor-stabilized plasma.

The Metabolic 7-Plex is the workhorse panel for diabetes, obesity, and metabolic research — used in glucose tolerance studies, bariatric surgery programs, incretin pharmacology, and metabolic phenotyping across academic and industry laboratories. Available in two configurations — Panel 1 with total GLP-1 (for overall L-cell secretion) and Panel 2 with active GLP-1 (for incretin receptor signaling) — the 7-Plex captures the hormonal network that governs glucose homeostasis in a single assay. For researchers transitioning from individual RIAs or ELISAs, the volume savings alone are transformative: seven hormones from 25 µL vs. 350–700 µL for seven separate assays.

Inquire About the 7-Plex View Analyte Details

Why Seven Hormones in One Well Transforms Metabolic Research

Glucose homeostasis is not regulated by any single hormone — it emerges from the coordinated, antagonistic, and temporally orchestrated actions of the enteroinsular axis. Insulin and glucagon are functional antagonists at the liver. GLP-1 and GIP potentiate insulin secretion (the incretin effect) while suppressing glucagon. Leptin signals long-term energy status to the hypothalamus. PYY suppresses appetite and slows gastric emptying. C-peptide distinguishes endogenous insulin secretion from exogenous administration. Measuring any subset in isolation produces an incomplete — and potentially misleading — picture of metabolic state.

 Research Applications of the 7-Plex
Diabetes & insulin resistance research: Simultaneous insulin, glucagon, C-peptide, and GLP-1 enables calculation of HOMA-IR, insulin:glucagon ratio, and the incretin effect — core metabolic parameters that require coordinated measurement of multiple hormones.
GLP-1 receptor agonist & DPP-IV inhibitor pharmacology: Active GLP-1 (Panel 2) quantifies the pharmacodynamic effect of DPP-IV inhibition and GLP-1R agonism; insulin and glucagon provide the downstream metabolic readout.
Bariatric & metabolic surgery research: GLP-1, PYY, and GIP are dramatically elevated after Roux-en-Y gastric bypass and sleeve gastrectomy; the 7-Plex captures the full post-surgical hormonal shift from a single sample.
Meal tolerance & glucose clamp studies: Serial 7-Plex measurements during metabolic challenges provide dynamic hormone response curves — insulin secretion rate, incretin effect magnitude, glucagon suppression — from minimal plasma volume at each timepoint.
Epidemiological & cohort studies: The 7-Plex's V-PLEX lot-to-lot bridging supports multi-year longitudinal metabolic phenotyping with documented analytical continuity across reagent transitions.

The Seven Analytes — Biological Roles

C-Peptide

Connecting peptide cleaved from proinsulin. Secreted in equimolar ratio with endogenous insulin. Clinical relevance: distinguishes endogenous insulin secretion from exogenous insulin administration. More stable than insulin ex vivo — useful when pre-analytical conditions are suboptimal.

GIP (Total)

Glucose-dependent insulinotropic polypeptide. K-cell incretin from the proximal small intestine. Research relevance: the second incretin alongside GLP-1. GIPR agonists in clinical development for obesity (tirzepatide is a dual GIP/GLP-1 receptor agonist).

GLP-1 (Active or Total)

Glucagon-like peptide-1. L-cell incretin from the distal ileum and colon. Panel 1: total GLP-1 — overall L-cell secretion. Panel 2: active GLP-1 (7-36 amide) — incretin receptor signaling. Core pharmacodynamic readout for DPP-IV inhibitors and GLP-1R agonists.

Glucagon

Pancreatic α-cell hormone. Counter-regulatory to insulin — stimulates hepatic glucose output. Research relevance: dysregulated in type 2 diabetes (impaired glucose-induced suppression). Requires protease inhibitor-stabilized collection.

Insulin

Pancreatic β-cell hormone. Primary anabolic signal. Research relevance: fasting levels reflect insulin sensitivity; glucose-stimulated levels reflect β-cell function. Must be interpreted with glucagon (ratio) and C-peptide (endogenous vs. exogenous).

Leptin

Adipocyte hormone signaling long-term energy stores. Research relevance: leptin resistance in obesity. Concentrations span 1–100+ ng/mL from lean to obese — ECL's wide dynamic range accommodates this without dilution.

PYY (Total)

Peptide YY. L-cell hormone co-secreted with GLP-1. Research relevance: suppresses appetite via hypothalamic Y2 receptors. Dramatically elevated after bariatric surgery. Key satiety signal alongside GLP-1.

Panel 1 vs. Panel 2 — Choosing the Right GLP-1 Assay

Feature	Panel 1 (Total GLP-1)	Panel 2 (Active GLP-1)
GLP-1 Measured	Total GLP-1 (all forms: 7-36 amide + 9-36 amide + others)	Active GLP-1 (7-36 amide + 7-37 only)
Other 6 Analytes	Identical: C-Peptide, GIP (total), Glucagon, Insulin, Leptin, PYY (total)
Best For	Nutrient-stimulated L-cell secretion studies; bariatric surgery research (overall GLP-1 output); conditions where DPP-IV activity may vary	Incretin receptor signaling studies; DPP-IV inhibitor pharmacodynamics; GLP-1R agonist PK/PD; studies focused on biologically active hormone
Biological Interpretation	Reflects total L-cell secretory capacity — how much GLP-1 is produced	Reflects receptor-activatable GLP-1 — how much can engage the GLP-1R. The ratio of active/total GLP-1 is a measure of DPP-IV activity in vivo
Pre-Analytical Sensitivity	Less sensitive to processing delays (inactive forms are stable)	Highly sensitive to processing delays — requires strict adherence to inhibitor + cold protocol
Common Study Types	Meal tolerance tests; bariatric surgery; metabolic phenotyping	DPP-IV inhibitor trials; GLP-1R agonist development; incretin effect quantification

If your research question involves both secretion and receptor activation, consider the 22-Plex which includes active, inactive, and total GLP-1 — enabling active/total ratio calculation within a single assay.

7-Plex Service Details

Service Package

Item	Full Service	Kit Only
Inhibitor Collection Tubes	Provided (DPP-IV inhibitor + aprotinin)	— Self-supplied
Sample Processing	Included with pre-analytical QC	— Self-run
7-Analyte Standard Curve	8-point, all 7 analytes	Calibrators provided
QC Samples	3 levels, duplicate	— User-prepared
Data Report	Full 7-analyte quantitative report	— Self-analysis
Raw ECL Data	Included	— Instrument-dependent

For Research Use Only. Not for diagnostic procedures.

How to Get Started

Choose Panel

Select Panel 1 (total GLP-1) or Panel 2 (active GLP-1) based on your research question. We'll confirm during study design consultation.

Collect & Ship

Use pre-loaded inhibitor tubes. Follow timed cold-processing protocol. Ship on dry ice with temperature monitoring.

Receive Metabolic Profile

Receive your 7-hormone quantitative report with pre-analytical QC documentation and methods for publication.

MSD 7-Plex vs. Traditional Metabolic Hormone Measurement

Feature	MSD Metabolic 7-Plex	Individual RIA (×7)	Individual ELISA (×7)
Sample Volume (7 hormones)	25 µL total	350–700 µL (50–100 µL each)	350–700 µL
Throughput	~70 seconds/plate	Hours–days (7 separate assays)	Hours (7 separate assays)
Dynamic Range	4–5 logs per analyte	2–3 logs	2–3 logs
Radioactive Waste	None	Yes — regulatory burden	None
Multiplex	7 analytes, 1 well	7 analytes, 7 wells	7 analytes, 7 wells
Lot Bridging	Documented (V-PLEX)	Kit-dependent	Kit-dependent
Rodent Compatibility	Excellent — 25 µL per timepoint	Poor — volume requirements often prohibitive for serial sampling	Poor

7-Plex Frequently Asked Questions

Can I use this panel for mouse studies?

The V-PLEX Metabolic 7-Plex described here is configured for human samples. For mouse metabolic studies, we offer analogous mouse-specific panels: a 6-Plex (C-Peptide, GLP-1 total, Glucagon, Insulin, Leptin, PYY total) and a 10-Plex that adds inflammatory markers (IL-6, TNF-α, MCP-1, Ghrelin active). Mouse panels also require protease inhibitor-stabilized plasma collection. Contact us for mouse-specific panel configurations and the smaller-volume collection protocols optimized for rodent metabolic studies.

What is the difference between Panel 1 and Panel 2 beyond GLP-1?

The six non-GLP-1 analytes are identical between Panel 1 and Panel 2: C-Peptide, GIP (total), Glucagon, Insulin, Leptin, and PYY (total). The only difference is the GLP-1 assay — total GLP-1 in Panel 1, active GLP-1 in Panel 2. This means your choice between panels depends entirely on whether your research question requires total L-cell secretion (Panel 1) or receptor-activatable incretin (Panel 2). If your study needs both active and total GLP-1 — for example, to calculate the active/total ratio as a measure of DPP-IV activity — the 22-Plex includes active, inactive, and total GLP-1 in a single panel.

How stable are the analytes after collection with protease inhibitors?

With DPP-IV inhibitor and aprotinin in the collection tube, and with immediate chilling and cold centrifugation: active GLP-1 is stable for at least 30 minutes at 4°C; total GLP-1, insulin, C-peptide, leptin, and PYY are stable for at least 2 hours at 4°C; glucagon is stable for 30–60 minutes at 4°C. Once plasma is separated and frozen at −80°C, all seven analytes are stable for at least 12 months with no more than 2 freeze-thaw cycles. Critical: these stability windows assume strict adherence to the inhibitor + cold protocol. Room-temperature handling, delayed centrifugation, or omission of inhibitors will compromise GLP-1 and glucagon measurements regardless of the assay platform used.

Is the 7-Plex available as a kit for self-run assays?

Yes. The V-PLEX Metabolic Panel 1 is available as a kit for laboratories with access to an MSD MESO QuickPlex or SECTOR instrument. The kit includes pre-coated plates, multi-analyte calibrator blend, detection antibody cocktail, and lot-specific datasheet. Protease inhibitor collection tubes must be sourced separately — we can provide supplier recommendations and inhibitor specifications for your collection protocol. Full-service (sample-to-data) is also available for laboratories without in-house MSD capability.

Are these assays validated for clinical diagnostic use?

No. The Metabolic 7-Plex is manufacturer-validated for research use only (RUO). It is suitable for preclinical studies, cohort research, biomarker discovery, and therapeutic development. It is not validated for clinical diagnostic procedures or patient management decisions. All data is reported with the explicit disclaimer that it should not be used as the sole basis for clinical decision-making.

Inquiry Basket